UAE Allergy Therapeutics Market Analysis

UAE Allergy Therapeutics Market Executive Summary

UAE Allergy Therapeutics Market was valued at $116 Mn in 2022 and is estimated to reach $205 Mn in 2030, exhibiting a CAGR of 7.4% during the forecast period.

Allergies are brought on by the immune system's sensitivity to benign environmental chemicals, or allergens. These allergies can include dust mites, pollen, mold, and common dietary triggers, including milk, eggs, soy, and almonds. Anaphylaxis, a severe allergic reaction, can result in a coma and difficulty breathing, while milder allergic reactions might bring symptoms like a runny nose and stinging eyes. Allergy control techniques include immunotherapy, avoiding allergens, and using prescription drugs such as antihistamines and nasal corticosteroids.

The UAE has a high incidence of allergies, which is a significant public health concern. Roughly 7% of the population has allergic rhinitis, which is probably a conservative estimate given the prevalence of other allergens like food and skin allergies. School-age children have a higher prevalence of up to 40%, highlighting the substantial influence on this younger group. The most common type of allergy is allergic rhinitis, which is mainly caused by dust and grass/pollen and causes symptoms including a runny nose, itchy eyes, congestion, and sneezing. Between 6 and 8% of kids may be allergic to certain foods. Common allergens include almonds, peanuts, milk, and eggs.

Prominent academic and medical establishments in the United Arab Emirates (UAE) are now conducting cutting-edge allergy research. The esteemed Mayo Clinic and Sharjah University are working together on a study that looks into the genetic risk factors and incidence of allergies in the United Arab Emirates. In particular, respiratory allergies and how they affect students' attendance at school are the focus.

A study is being carried out by the Sheikh Zayed Institute for Pediatric Ophthalmology and Genetics with the goal of improving the identification and treatment of food allergies in children. With possible ramifications for international healthcare practices, this program, which applies genetic testing and individualized treatment approaches, reflects a commitment to increasing the knowledge and management of allergies in the United Arab Emirates.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Allergies: The rising incidence of allergic conditions in the population, such as food allergies, skin allergies, and respiratory allergies, is the main factor driving the need for allergy therapy drugs.

Changing Lifestyles and Environmental Factors: Increased exposure to environmental variables, urbanization, and lifestyle changes can all lead to a rise in the prevalence of allergies. Increased demand for allergy drugs may result from factors including dietary changes and air pollution.

Awareness and Education Programs: Increased demand for allergy drugs might result from raising awareness of allergies through educational initiatives and public health campaigns, which can encourage early diagnosis and treatment.

Market Restraints

Treatment Compliance and Adherence: The effectiveness of allergy medications, especially long-term regimens like immunotherapy, depends on consistent adherence. Therapy effectiveness may be reduced and market expansion may be impeded by ineffective patient adherence brought on by expenses, challenges, or side effects.

Regulatory Hurdles: Patients may not have timely access to innovative drugs if the licensing process for novel drugs and therapies is postponed due to the strict regulatory procedures that must be followed. The licensing process's delay may impede the market's expansion.

High Cost of Treatment: A considerable percentage of the population cannot afford many of the modern and successful allergy medicines, such as biologics and sublingual immunotherapy, due to their high cost. This may restrict patients access to the best possible care and market penetration.

Healthcare Policies and Regulatory Landscape

The United Arab Emirates (UAE) has multiple agencies in charge of regulating allergy treatment medications. The main regulatory authority in charge of approving, registering, and overseeing pharmaceuticals, including allergy treatments, is the Ministry of Health and Prevention (MOHAP). To guarantee that safety and efficacy requirements are met, pharmaceutical companies must acquire MOHAP approval before selling or distributing drugs. MOHAP's Pharmaceutical Services Department (PSD) is in charge of drug imports and registration, while Emirates Health Services (EHS) is in charge of keeping an eye on medical institutions. Healthcare supervision in Dubai is under the purview of the Dubai Health Authority (DHA), whereas the Department of Health (DOH) in Abu Dhabi is in charge of healthcare regulation. Professional education is enhanced by the Dubai Pharmacy College, while research and development endeavours are supported by Dubai Science Park (DSP). Drug imports are regulated by customs and border protection agencies, and groups such as the UAE Genetic Diseases Association may fund allergy-related genetic research.

Competitive Landscape

Key Players

• Sanofi
• GlaxoSmithKline (GSK)
• Novartis
• Merck & Co.
• AstraZeneca
• Bayer
• Pfizer
• Teva Pharmaceutical Industries
• Almirall
• Chiesi Farmaceutici